Janux Therapeutics, Inc. 8-K

What Happened
Janux Therapeutics, Inc. announced its financial results for the fiscal year ended December 31, 2025 via a press release issued on February 26, 2026. The company furnished the press release as Exhibit 99.1 to Form 8-K; the filing states this information is being furnished (not filed) under the Securities Exchange Act.

Key Details

• Event: Press release announcing FY2025 financial results issued on February 26, 2026.
• Reporting period: Results cover the year ended December 31, 2025.
• Filing status: The press release was furnished as Exhibit 99.1 and is not deemed “filed” for purposes of Section 18 of the Exchange Act (i.e., furnished, not subject to Section 18 liability).
• Signature: Form 8-K was signed by David Campbell, Ph.D., President and Chief Executive Officer.

Why It Matters
This filing signals that Janux has released its annual operating and financial results; investors should review the attached press release for revenue, profit/loss, cash position, and operational highlights. Because the release is furnished (not filed), the company is providing the information to the market but has limited Section 18 liabilities for it—investors should watch for subsequent filings (e.g., Form 10-K) for audited and fully incorporated financial statements and management discussion.